PE 22-28 | Peptide Research Hub

At a Glance

PE 22–28 is a shortened spadin-derived peptide described in the literature as a TREK-1 (KCNK2) channel inhibitor with antidepressant-like activity in rodent models, alongside reported effects on neurogenesis/synaptogenesis markers in experimental settings. [PMID: 28955242]

⚠️ Research Status: PE 22–28 is not an approved medication. This page is educational and intentionally does not include protocols/dosing.

Mechanism of Action (TBD)

Described as inhibiting TREK-1, a two-pore-domain potassium channel implicated in stress and antidepressant pharmacology in various research frameworks. [PMID: 28955242]

Evidence Summary

Low Confidence Animal Study 3-10 Years

Preclinical study reports TREK-1 inhibition in vitro and antidepressant-like effects in multiple rodent behavioral models. [PMID: 28955242]

Safety & Unknowns

Human clinical efficacy and safety are not established by preclinical rodent models.
CNS-active mechanisms may have context-dependent risks and interactions.

Regulatory Status

Region	Status
United States (FDA)	Not approved
European Union (EMA)	Not approved
WADA	Check current list (status may change)

Changelog

Date	Change
2026-01-23	Added dossier and linked primary literature